Immix Biopharma
IMMX
28 hedge funds and large institutions have $5.43M invested in Immix Biopharma in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 1 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 1
292% more capital invested
Capital invested by funds: $1.39M → $5.43M (+$4.04M)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
75% more funds holding
Funds holding: 16 → 28 (+12)
1.96% more ownership
Funds ownership: 2.06% → 4.02% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$465K |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$452K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$245K |
| 4 |
Renaissance Technologies
New York
|
+$147K |
| 5 |
Morgan Stanley
New York
|
+$145K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Koshinski Asset Management
Decatur,
Illinois
|
-$174K |
| 2 |
ICG
InterOcean Capital Group
Nashville,
Tennessee
|
-$18.1K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$2.51K |
| 4 |
BlackRock
New York
|
-$1.26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $2.71K | +$1.51K | +334 | +586% |
|
27
Osaic Holdings
Scottsdale,
Arizona
| $2.42K | – | – | – |
|
|
28
Koshinski Asset Management
Decatur,
Illinois
| – | -$174K | -51,001 | Closed |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$308 | +68 | New |
|
IMMX Hedge Fund Activity: Q4 2023 in Review
28 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q4 2023, worth a combined $5.43M — up 292% from $1.39M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IMMX positions and 1 closed out — a net gain of 12 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $465K. The largest seller was Koshinski Asset Management, exiting entirely with an estimated $174K sold.
- 28 institutional investors held Immix Biopharma (IMMX) as of Q4 2023, up from 16 in Q3 2023.
- Funds reported $5.43M of Immix Biopharma stock for Q4 2023, up 292% quarter-over-quarter.
- 13 funds opened new Immix Biopharma positions in Q4 2023 and 1 closed out, a net change of +12 holders.
- The largest Immix Biopharma buyer in Q4 2023 was EAM Investors, an estimated $465K added.
- The largest Immix Biopharma seller in Q4 2023 was Koshinski Asset Management, an estimated $174K sold.
Based on aggregated 13F filings for Q4 2023.